Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase II Clinical Study of Erlotinib for Treatment of Myelodysplastic Syndromes

Rami S. Komrokji, MD, Alan F. List, MD, Daohai Yu, Ph.D, William J Fulp, Yuraima Rodriguez, Pamela S Smith, RN, Jeffrey E. Lancet, MD

Blood (2011) 118 (21): 1714.

https://doi.org/10.1182/blood.V118.21.1714.1714

Published: 2011

Journal Articles

A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in relapsed or Refractory Acute Myeloid Leukemia

Rami S. Komrokji, MD, Javier Pinilla-Ibarz, MD, PhD, Daohai Yu, Ph.D, Lisa Nardelli, Christopher Cubitt, Xiuhua Zhao, Hugo F. Fernandez, MD, Alan F List, MD, Jeffrey E. Lancet, MD

Blood (2011) 118 (21): 2604.

https://doi.org/10.1182/blood.V118.21.2604.2604

Published: 2011

Journal Articles

A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Daohai Yu, Ph.D, Anjali S. Advani, MD, Tammy Searles, RN, Mikkael A. Sekeres, MD, MS, Alan F. List, MD

Blood (2011) 118 (21): 2600.

https://doi.org/10.1182/blood.V118.21.2600.2600

Published: 2011

Journal Articles

Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study

Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Daohai Yu, Ph.D, Enrique Santana, RN, Lulu Yan, MS, Pamela S Smith, RN, Sara Tinsley, ARNP, Darcie Deaver, ARNP, Ling Zhang, MD, Alan F. List, MD

Blood (2010) 116 (21): 1854.

https://doi.org/10.1182/blood.V116.21.1854.1854

Published: 2010

Journal Articles

High Rate of Uncaptured Myelodysplastic Syndrome Cases at the State Cancer Registry Level

Christopher R. Cogle, MD, Michelle R Iannacone, Ashley Cole, Daohai Yu, Ph.D, Alan F. List, Dana Rollison, PhD

Blood (2010) 116 (21): 1890.

https://doi.org/10.1182/blood.V116.21.1890.1890

Published: 2010

Journal Articles

A Keyword Search Strategy to Identify Missed Cases of Myelodysplastic Syndromes in Population-Based Cancer Registries.

Christopher R Cogle, MD, Ashley Cole, Iman Imanirad, M.D., Leena Kamat, Daohai Yu, Ph.D., Alan F List, MD, Dana E Rollison, PhD

Blood (2009) 114 (22): 4852.

https://doi.org/10.1182/blood.V114.22.4852.4852

Published: 2009

Journal Articles

Hypoalbuminemia (< 3.0 g/dl) and Poor Karnofsky Performance Score (<80) at Day 90 Following Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Are Independent Predictors of Worse Non-Relapse Survival (NRS) and Overall Survival (OS): A Multivariable Analysis Approach of Various Clinical, Laboratory and Pharmacologic Parameters

Mohamed A Kharfan-Dabaja, MD, Julio C. Chavez, Eduardo Ivan Fernandez-Vertiz, Daohai Yu, Weiwei Zhu, Janelle Perkins, Teresa Field, Ernesto Ayala, Hugo F. Fernandez, Melissa Alsina, Lia Perez, Jyotishankar Raychaudhuri, J. Leonel Ochoa-Bayona, Linda Brand, Dan Sullivan, Claudio Anasetti

Blood (2008) 112 (11): 4329.

https://doi.org/10.1182/blood.V112.11.4329.4329

Published: 2008

Journal Articles

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

Blood (2007) 109 (12): 5136–5142.

https://doi.org/10.1182/blood-2006-11-056754

Published: 2007

Journal Articles

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

Pankaj Gupta, MD, Ben L. Sanford, MS, Daohai Yu, PhD, Ravi Vij, MD, David D. Hurd, MD, Olatoyosi Odenike, MD, Clara D. Bloomfield, MD, Robert P. Hasserjian, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 2665.

https://doi.org/10.1182/blood.V108.11.2665.2665

Published: 2006

Journal Articles

CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.

Gerard Lozanski, MD, Ben Sanford, MS, Daohai Yu, PhD, Rebecca Pearson, MLT, Colin Edwards, MS, John C. Byrd, MD, Richard A. Larson, MD, Clara D. Bloomfield, MD, Wendy Stock, MD

Blood (2006) 108 (11): 2293.

https://doi.org/10.1182/blood.V108.11.2293.2293

Published: 2006

Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 145.

https://doi.org/10.1182/blood.V106.11.145.145

Published: 2005

Journal Articles

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

Wendy Stock, MD, Jeffrey Johnson, MS, Daohai Yu, PhD, Diane Bennett, BSN, Dorie Sher, BS, Richard M. Stone, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Meir Wetzler, MD, James W. Vardiman, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 1833.

https://doi.org/10.1182/blood.V106.11.1833.1833

Published: 2005

Journal Articles

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Meir Wetzler, MD, Daohai Yu, PhD, Olatoyosi Odenike, MD, Eric J. Feldman, MD, David D. Hurd, MD, Eva Hoke, Vera Hars, Richard A. Larson, MD

Blood (2005) 106 (11): 1097.

https://doi.org/10.1182/blood.V106.11.1097.1097

Published: 2005

NARROW

A Phase II Clinical Study of Erlotinib for Treatment of Myelodysplastic Syndromes

A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study

High Rate of Uncaptured Myelodysplastic Syndrome Cases at the State Cancer Registry Level

A Keyword Search Strategy to Identify Missed Cases of Myelodysplastic Syndromes in Population-Based Cancer Registries.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) in Patients with Myelodysplastic Syndrome (MDS): Cancer and Leukemia Group B Study 10105.

CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only